Developing the Next Generation of Dermatology Treatments
Incyte’s science-first approach and heritage in immunology has formed the foundation of our company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need.
Our research and development efforts in dermatology are initially focused on leveraging our knowledge of the JAK-STAT pathway. We are exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa.
Research has shown that the JAK-STAT pathway mediates the cellular effects of cytokines involved in the pathogenesis of many immune-mediated dermatologic conditions. We strive to identify and develop therapies to modulate immune pathways driving uncontrolled inflammation to help restore normal immune function and bring the body closer to homeostasis.
Resources
FOR HEALTHCARE PROFESSIONALS
This website helps healthcare professionals to better support their patients with Vitiligo.
Incyte is committed to providing timely and accurate product information to healthcare professionals upon request. If you need medical information or have a medical question, please contact our medical team at eumedinfo@incyte.com or visit incyteglobalmedicalinformation.com.
To report a possible Adverse Event (AE) or Product Complaint related to an Incyte product, contact Incyte Global Medical Information. Alternatively, you can report AEs by email: eumedinfo@incyte.com.